{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["140(16)"],"submitter":["Soumerai JD"],"funding":["NCI NIH HHS"],"journal":["Blood"],"pagination":["1822-1826"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9837428"],"repository":["biostudies-literature"],"pubmed_title":["Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma."],"pmcid":["PMC9837428"],"funding_grant_id":["P30 CA021765","R01 CA196703","P30 CA008748","P50 CA097274"],"pubmed_authors":["Liu H","Dogan A","Lei M","Kurilovich A","El-Jawahri AR","Mohr S","Duffy J","Martin H","Menard C","Rimsza LM","Zelenetz AD","Mecca C","Soumerai JD","Abramson JS","Nardi V","Wang Y","Bantilan K","Grewal RK","Postovalova E","Yang L","Harkins S","Rosenthal A","Chiarle R","Kudryashova O","Louissaint A"],"additional_accession":[]},"is_claimable":false,"name":"Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.","description":null,"dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-22T17:26:47.209Z","creation":"2025-04-06T02:06:58.154Z"},"accession":"S-EPMC9837428","cross_references":{"pubmed":["35802834"],"doi":["10.1182/blood.2022015443"]}}